<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03099824</url>
  </required_header>
  <id_info>
    <org_study_id>GTO-003</org_study_id>
    <nct_id>NCT03099824</nct_id>
  </id_info>
  <brief_title>A Phase 1 Study of the Safety and Pharmacokinetics of GC4711 (Oral Capsule) Compared to GC4419 (IV Infusion) and GC4711 (IV Infusion) in Healthy Volunteers</brief_title>
  <official_title>A Phase 1, Open-label Study to Compare the Safety and Pharmacokinetics of Various Formulations of Orally Administered Superoxide Dismutase Mimetic GC4711 With Intravenously Administered Superoxide Dismutase Mimetic GC4419 or GC4711 in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Galera Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Galera Therapeutics, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the phase 1, GTO-003 clinical study is to determine the safety and&#xD;
      pharmacokinetics of a single dose of a new drug called GC4711 when given as an oral capsule.&#xD;
      This study will compare capsules of GC4711 when given orally to a similar drug, GC4419, or&#xD;
      GC4711 when either is given as an intravenous infusion.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 16, 2018</start_date>
  <completion_date type="Actual">January 27, 2020</completion_date>
  <primary_completion_date type="Actual">January 27, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events and Laboratory Abnormalities</measure>
    <time_frame>From randomization through study completion (estimated up to 13 days)</time_frame>
    <description>Number of Participants With Treatment-Emergent Adverse Events and/or Laboratory Abnormalities.</description>
  </primary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">56</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>GC4419 IV + GC4711 Oral G-101 (82mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>GC4419 IV + GC4711 Oral G-101 (164mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>GC4419 IV + GC4711 Oral G-101 (246mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>GC4419 IV + GC4711 Oral G-111 (175mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>GC4419 IV + GC4711 Oral G-112 (145mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>GC4711 IV + GC4711 Oral G-119 (233mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>GC4711 IV + GC4711 Oral G-125 (233mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GC4711 Oral Capsule G-101</intervention_name>
    <description>82 mg (1 capsule)</description>
    <arm_group_label>GC4419 IV + GC4711 Oral G-101 (82mg)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IV GC4419</intervention_name>
    <description>GC4419 will be infused IV as a single dose of 27 mg in 247 mL normal saline, totaling 250 mL, over a 60-minute period using a programmable pump.</description>
    <arm_group_label>GC4419 IV + GC4711 Oral G-101 (164mg)</arm_group_label>
    <arm_group_label>GC4419 IV + GC4711 Oral G-101 (246mg)</arm_group_label>
    <arm_group_label>GC4419 IV + GC4711 Oral G-101 (82mg)</arm_group_label>
    <arm_group_label>GC4419 IV + GC4711 Oral G-111 (175mg)</arm_group_label>
    <arm_group_label>GC4419 IV + GC4711 Oral G-112 (145mg)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GC4711 Oral Capsule G-101</intervention_name>
    <description>164 mg (2 capsules)</description>
    <arm_group_label>GC4419 IV + GC4711 Oral G-101 (164mg)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GC4711 Oral Capsule G-101</intervention_name>
    <description>246 mg (3 capsules)</description>
    <arm_group_label>GC4419 IV + GC4711 Oral G-101 (246mg)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GC4711 Oral Capsule G-111</intervention_name>
    <description>175 mg (1 capsule)</description>
    <arm_group_label>GC4419 IV + GC4711 Oral G-111 (175mg)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GC4711 Oral Capsule G-112</intervention_name>
    <description>145 mg (1 capsule)</description>
    <arm_group_label>GC4419 IV + GC4711 Oral G-112 (145mg)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GC4711 Oral Capsule G-119</intervention_name>
    <description>233 mg (1 capsule)</description>
    <arm_group_label>GC4711 IV + GC4711 Oral G-119 (233mg)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GC4711 Oral Capsule G-125</intervention_name>
    <description>233 mg (1 capsule)</description>
    <arm_group_label>GC4711 IV + GC4711 Oral G-125 (233mg)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IV GC4711</intervention_name>
    <description>GC4711 will be infused IV as a single dose of 30 mg in 250 mL normal saline, totaling 251 mL, over a 60-minute period using a programmable pump.</description>
    <arm_group_label>GC4711 IV + GC4711 Oral G-119 (233mg)</arm_group_label>
    <arm_group_label>GC4711 IV + GC4711 Oral G-125 (233mg)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Healthy men and women between 18 and 50 years (inclusive) of age;&#xD;
&#xD;
          2. Subjects who provide written informed consent&#xD;
&#xD;
          3. Body Mass Index (BMI) 18 to 32 kg/m2 (inclusive) and weighing at least 50 kg during&#xD;
             Screening and at Baseline. Every effort will be made to enroll across BMI range to&#xD;
             evaluate relation between dose and weight;&#xD;
&#xD;
          4. Subjects in general good health in the investigator's opinion&#xD;
&#xD;
          5. Chest X-ray free of clinically significant abnormalities&#xD;
&#xD;
          6. Blood pressure and heart rate within normal limits&#xD;
&#xD;
          7. Female subjects must:&#xD;
&#xD;
               1. Have a negative serum pregnancy test during Screening and a negative urine&#xD;
                  pregnancy test at Baseline, and be willing and able to use a medically acceptable&#xD;
                  method of birth control or be postmenopausal.&#xD;
&#xD;
               2. Be non-lactating&#xD;
&#xD;
               3. Be at least two years postmenopausal, surgically sterile or practicing effective&#xD;
                  contraception&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of clinically significant illness, medical condition, or laboratory&#xD;
             abnormality within three months&#xD;
&#xD;
          2. History of any clinically significant cardiovascular, hepatic, renal, or&#xD;
             gastrointestinal abnormality;&#xD;
&#xD;
          3. History of hypotension&#xD;
&#xD;
          4. Known contraindication, hypersensitivity and/or allergy to investigational products&#xD;
&#xD;
          5. Use of any prescription or over-the-counter medication within one week prior to&#xD;
             baseline;&#xD;
&#xD;
          6. Anticipated need for any medication during the course of the study&#xD;
&#xD;
          7. Use of nitrates or erectile dysfunction drugs such as phosphodiesterase type 5 (PDE 5)&#xD;
             inhibitors (e.g., sildenafil, tadalafil, or similar agents), from 24 hours prior to&#xD;
             screening throughout participation in the study;&#xD;
&#xD;
          8. Use of or other drugs that may, in the judgment of the treating investigator, create a&#xD;
             risk for a precipitous decrease in blood pressure&#xD;
&#xD;
          9. Presence of orthostatic hypotension at screening or baseline&#xD;
&#xD;
         10. Use of any vitamin or mineral supplement 24 hours prior to dosing, or anticipated use&#xD;
             of any vitamin or mineral supplement throughout the duration of the study;&#xD;
&#xD;
         11. Positive HIV, Hepatitis B or Hepatitis C serology at Screening;&#xD;
&#xD;
         12. Known history of substance abuse, drug addiction, or alcoholism within 3 years&#xD;
&#xD;
         13. Anticipated inability to abstain from alcohol, tobacco, or caffeine use from 48 hours&#xD;
             prior to the administration of study drug and throughout the duration of the study;&#xD;
&#xD;
         14. Positive drug and alcohol toxicology screens during Screening and at Baseline;&#xD;
&#xD;
         15. History of smoking or any use of a tobacco product within six months prior to&#xD;
             Baseline;&#xD;
&#xD;
         16. Donation of blood or blood products within 30 days prior to the Baseline and through&#xD;
             duration of study;&#xD;
&#xD;
         17. Mentally unstable or incapable of being compliant with the protocol&#xD;
&#xD;
         18. Receipt of an investigational test substance within three months prior to the first&#xD;
             dose of investigational products (GC4419, GC4711, or placebo), or anticipated&#xD;
             receiving any investigational products (including placebo on another investigational&#xD;
             study) other than GC4711 and GC4419 during the course of this study;&#xD;
&#xD;
         19. Subject has previously participated in this study, or in a prior study of GC4419,&#xD;
             GC4711 or GC4702.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jon T Holmlund, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Chief Medical Officer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Nucleus Network</name>
      <address>
        <city>Melbourne</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 20, 2017</study_first_submitted>
  <study_first_submitted_qc>March 28, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 4, 2017</study_first_posted>
  <last_update_submitted>March 1, 2021</last_update_submitted>
  <last_update_submitted_qc>March 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Avasopasem manganese</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

